Protagonist Therapeutics (PTGX) Metrics: History & Chart

Protagonist Therapeutics, Inc.(PTGX)

Biotechnology · Newark, CA

$138.69-1.94 (-1.38%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.

Newark, CA

141 employees

www.protagonist-inc.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Dinesh V. Patel

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-1.27%
30D Total Return	-3.49%
YTD Total Return	+61.01%
1Y Total Return	+116.92%
3Y Total Return	+766.50%
5Y Total Return	+681.69%
10Y Total Return	+547.44%
15Y Total Return	N/A
20Y Total Return	N/A

2026	+61.01%
2025	+126.27%
2024	+68.34%
2023	+110.17%
2022	-68.10%
2021	+69.64%
2020

CAGR TTM	+116.12%
CAGR 3Y	+105.36%
CAGR 5Y	+50.88%
CAGR 10Y	+20.54%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	136.05
PE Ratio Avg TTM	139.11
PE Ratio Avg 3Y	61.10
Current VS TTM Avg	-2.20%
Current VS 3Y Avg	+122.67%
Current VS 5Y Avg	+122.67%

All Metrics

PTGX Valuation Metrics

PTGX Stock Price Metrics

PTGX Dividend Metrics

PTGX Growth Rate Metrics

PTGX Discounted Cash Flow Metrics

PTGX Returns By Period

PTGX Yearly Returns

PTGX Average Annual Returns By Period (CAGR)

PTGX Revenue Metrics

PTGX PE Ratio Metrics

PTGX PS Ratio Metrics

PTGX PB Ratio Metrics

PTGX Price to Free Cash Flow Ratio Metrics

PTGX Debt to Equity Ratio Metrics

PTGX PEG Ratio Metrics

PTGX FCF Yield

PTGX Earnings Yield

PTGX EBITDA Yield

PTGX OCF Yield

PTGX EV/EBIT Ratio Metrics

PTGX EV/EBITDA Ratio Metrics

PTGX EV/Assets Ratio Metrics

PTGX EV/Sales Ratio Metrics

PTGX Current Ratio Metrics

PTGX Quick Ratio Metrics

PTGX ROIC Metrics

PTGX Return on Assets Metrics

PTGX Return on Equity Metrics

PTGX Net Profit Margin Metrics

PTGX Gross Profit Margin Metrics

PTGX Tax Rate Metrics

PS Ratio	35.41
PS Ratio Avg TTM	70.38
PS Ratio Avg 3Y	16.67
Current VS TTM Avg	-49.68%
Current VS 3Y Avg	+112.46%
Current VS 5Y Avg	+46.32%

PB Ratio	11.87
PB Ratio Avg TTM	10.38
PB Ratio Avg 3Y	6.34
Current VS TTM Avg	+14.34%
Current VS 3Y Avg	+87.22%
Current VS 5Y Avg	+175.09%

PFCF Ratio	76.47
PFCF Ratio Avg TTM	96.70
PFCF Ratio Avg 3Y	52.90
Current VS TTM Avg	-20.92%
Current VS 3Y Avg	+44.57%
Current VS 5Y Avg	+44.57%

Debt/Equity Ratio	0.01
Debt/Equity Ratio Avg TTM	0.02
Debt/Equity Ratio Avg 3Y	0.01
Current VS TTM Avg	-28.14%
Current VS 3Y Avg	-15.27%
Current VS 5Y Avg	-35.10%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	1.31%
FCF Yield Avg TTM	1.07%
FCF Yield Avg 3Y	5.06%
Current VS TTM Avg	+22.65%
Current VS 3Y Avg	-74.12%
Current VS 5Y Avg	-74.12%

Earnings Yield	0.74%
Earnings Yield Avg TTM	0.72%
Earnings Yield Avg 3Y	4.13%
Current VS TTM Avg	+2.77%
Current VS 3Y Avg	-82.09%
Current VS 5Y Avg	-82.09%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	164.12
Ev/Ebit Ratio Avg TTM	233.04
Ev/Ebit Ratio Avg 3Y	100.55
Current VS TTM Avg	-29.57%
Current VS 3Y Avg	+63.22%
Current VS 5Y Avg	+63.22%

Ev/Ebitda Ratio	159.89
Ev/Ebitda Ratio Avg TTM	219.04
Ev/Ebitda Ratio Avg 3Y	94.19
Current VS TTM Avg	-27.00%
Current VS 3Y Avg	+69.75%
Current VS 5Y Avg	+69.75%

Ev/Assets Ratio	10.81
Ev/Assets Ratio Avg TTM	9.44
Ev/Assets Ratio Avg 3Y	5.52
Current VS TTM Avg	+14.56%
Current VS 3Y Avg	+95.81%
Current VS 5Y Avg	+208.41%

Ev/Sales Ratio	33.95
Ev/Sales Ratio Avg TTM	68.80
Ev/Sales Ratio Avg 3Y	15.78
Current VS TTM Avg	-50.66%
Current VS 3Y Avg	+115.09%
Current VS 5Y Avg	+63.71%

Current Ratio	21.71
Current Ratio Avg TTM	16.44
Current Ratio Avg 3Y	14.80
Current VS TTM Avg	+32.06%
Current VS 3Y Avg	+46.63%
Current VS 5Y Avg	+76.60%

Quick Ratio	21.71
Quick Ratio Avg TTM	16.44
Quick Ratio Avg 3Y	14.80
Current VS TTM Avg	+32.06%
Current VS 3Y Avg	+46.63%
Current VS 5Y Avg	+76.60%

ROIC	6.74%
ROIC Avg 3Y	(3.52%)
ROIC Avg 5Y	(19.75%)
Current VS 3Y Avg	+291.63%
Current VS 5Y Avg	+134.13%
Current VS 10Y Avg	+117.41%

ROA	9.36%
ROA Avg TTM	0.37%
ROA Avg 3Y	(0.60%)
Current VS TTM Avg	+2419.49%
Current VS 3Y Avg	+1657.40%
Current VS 5Y Avg	+230.88%

ROE	9.85%
ROE Avg TTM	(2.78%)
ROE Avg 3Y	0.82%
Current VS TTM Avg	+453.85%
Current VS 3Y Avg	+1098.22%
Current VS 5Y Avg	+158.43%

Net Profit Margin	29.40%
Net Profit Margin Avg TTM	(395.13%)
Net Profit Margin Avg 3Y	(250.60%)
Current VS TTM Avg	+107.44%
Current VS 3Y Avg	+111.73%
Current VS 5Y Avg	+110.77%

Gross Profit Margin	99.86%
Gross Pft Margin Avg TTM	99.86%
Gross Pft Margin Avg 3Y	100.00%
Current VS TTM Avg	+0.00%
Current VS 3Y Avg	-0.14%
Current VS 5Y Avg	+40.89%

Tax Rate	1.37%
Tax Rate Avg 3Y	(12.28%)
Tax Rate Avg 5Y	(12.28%)
Current VS 3Y Avg	+111.17%
Current VS 5Y Avg	+111.17%
Current VS 10Y Avg	+111.17%